ERBB2 and breast cancer: In particular, Li et al., using syngeneic and humanized tumor models including HER2+mammary cancer models, showed that combination of CD39 and anti-PD1 blockade was dependent on the activation of the NLRP3 inflammasome in macrophages and the subsequent release of inflammatory cytokines [122].